Literature DB >> 11241385

Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes.

M Zarate-Lagunes1, W J Gu, V Blanchard, C Francois, M P Muriel, A Mouatt-Prigent, B Bonici, A Parent, A Hartmann, J Yelnik, G A Boehme, L Pradier, S Moussaoui, B Faucheux, R Raisman-Vozari, Y Agid, A Brice, E C Hirsch.   

Abstract

The etiology of Parkinson's disease is unknown, but the gene involved in an autosomic recessive form of the disease with early onset has recently been identified. It codes for a protein with an unknown function called parkin. In the present study we produced a specific polyclonal antiserum against human parkin. Immunohistochemical analysis showed that parkin is expressed in neuronal perikarya and processes but also in glial and blood vessels in the primate brain (human and monkey). Electron microscopy indicated that parkin immunoreactivity is mostly located in large cytoplasmic vesicles and at the level of the endoplasmic reticulum. Parkin was expressed heterogeneously in various structures of the brain. It was detectable in the dopaminergic systems at the level of the perikarya in the mesencephalon but also in the striatum. However, parkin was also expressed by numerous nondopaminergic neurons. The staining intensity of parkin was particularly high in the hippocampal formation, the pallidal complex, the red nucleus, and the cerebellum. Comparison of control subjects with patients with Parkinson's disease and control animals with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated animals revealed a loss of parkin-immunoreactive neurons only in the substantia nigra pars compacta. Furthermore, the surviving dopaminergic neurons in the parkinsonian state continued to express parkin at a level similar to that observed in the control situation. These data indicate that parkin is a widely expressed protein. Thus, the degeneration of dopaminergic neurons in familial cases of Parkinson's disease with autosomal recessive transmission cannot be explained solely in terms of an alteration of this protein. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241385     DOI: 10.1002/cne.1096

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  6 in total

1.  Postmortem studies in Parkinson's disease.

Authors:  Andreas Hartmann
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

2.  Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.

Authors:  Soraya Scuderi; Valentina La Cognata; Filippo Drago; Sebastiano Cavallaro; Velia D'Agata
Journal:  Biomed Res Int       Date:  2014-07-16       Impact factor: 3.411

3.  Rab GTPases in Parkinson's disease: a primer.

Authors:  Antonio Jesús Lara Ordóñez; Rachel Fasiczka; Yahaira Naaldijk; Sabine Hilfiker
Journal:  Essays Biochem       Date:  2021-12-22       Impact factor: 8.000

4.  Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.

Authors:  Pascaline Aimé; Xiaotian Sun; Neela Zareen; Apeksha Rao; Zachary Berman; Laura Volpicelli-Daley; Paulette Bernd; John F Crary; Oren A Levy; Lloyd A Greene
Journal:  J Neurosci       Date:  2015-07-29       Impact factor: 6.167

Review 5.  Oxidative stress induces autophagy in response to multiple noxious stimuli in retinal ganglion cells.

Authors:  Wen-jian Lin; Hong-yu Kuang
Journal:  Autophagy       Date:  2014-10-01       Impact factor: 16.016

Review 6.  Post-translational modification of Parkin and its research progress in cancer.

Authors:  Dan Ding; Xiang Ao; Ying Liu; Yuan-Yong Wang; Hong-Ge Fa; Meng-Yu Wang; Yu-Qi He; Jian-Xun Wang
Journal:  Cancer Commun (Lond)       Date:  2019-11-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.